Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/46517
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChonlaphat Sukasemen_US
dc.contributor.authorSadeep Medhasien_US
dc.contributor.otherFaculty of Medicine, Ramathibodi Hospital, Mahidol Universityen_US
dc.date.accessioned2019-08-28T06:00:21Z-
dc.date.available2019-08-28T06:00:21Z-
dc.date.issued2018-07-02en_US
dc.identifier.citationGenomics-Driven Healthcare: Trends in Disease Prevention and Treatment. (2018), 239-261en_US
dc.identifier.other2-s2.0-85063206583en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85063206583&origin=inwarden_US
dc.identifier.urihttp://repository.li.mahidol.ac.th/dspace/handle/123456789/46517-
dc.description.abstract© Springer Nature Singapore Pte Ltd. 2018. Genetic variability among drug-metabolizing enzymes (DMEs) and transporters influences the pharmacokinetics of the drug and is associated with marked interindividual variability in therapeutic effects and toxicity. Therapeutic drug monitoring (TDM) can facilitate the individualization of dose adjustment of the drug by measuring the plasma concentrations of drug. TDM can be incorporated with the pharmacogenomics, and the metabolic status of the patient can be characterized to optimize the dosage regimen according to the patient's needs. Several polymorphisms among cytochrome P450 (CYP) and phase II enzymes that contribute to the adverse drug reactions (ADRs) have been updated on a regular basis in PharmGKB. A number of pharmacogenomic markers are reported by the Food and Drug Administration and Clinical Pharmacogenetics Implementation Consortium (CPIC) among DMEs for commonly used drugs that are potentially associated with variability in drug response. This review focuses on the genetic polymorphisms of phases I and II DMEs and their associations with drug responses. The drugs discussed in this review requiring a pharmacogenomic test before being prescribed includes efavirenz, voriconazole, clopidogrel, warfarin, tamoxifen, irinotecan, tacrolimus, azathioprine, and risperidone. This chapter also presents the application of pharmacogenomics in the clinic and patient counseling. Finally, a section focuses on the future perspectives of pharmacogenomics and the translation of pharmacogenomic research into routine clinical care.en_US
dc.rightsMahidol Universityen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85063206583&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleClinical pharmacogenomics and personalized medicine: New strategies to maximize drug efficacy and avoid adverse drug reactionen_US
dc.typeChapteren_US
dc.rights.holderSCOPUSen_US
dc.identifier.doi10.1007/978-981-10-7506-3_13en_US
Appears in Collections:Scopus 2018

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.